Weekly Digest – April 2026 Weekly Digest – April 2026 20 April 2026: Blenrep approved in China for treatment of 2L+ relapsed/refractory multiple myeloma GSK has announced that China’s NMPA has approved Blenrep in combination with bortezomib and dexamethasone for […]
Weekly Digest – April 2026 Weekly Digest – April 2026 20 April 2026: U.S. FDA grants Priority Review to sBLA for PADCEV + Keytruda as perioperative treatment for MIBC regardless of Cisplatin eligibility U.S. Food and Drug Administration has granted […]
Weekly Digest – April 2026 Weekly Digest – April 2026 22 April 2026: Trastuzumab Ruikang has received BTD from China’s NMPA for the treatment of HER2‑positive breast cancer Jiangsu Hengrui Pharmaceuticals announced that its HER2-targeting ADC Trastuzumab Ruikang in combination […]
Weekly Digest – April 2026 Weekly Digest – April 2026 22 April 2026: SHR‑A2102 has received BTD from China’s NMPA for the treatment of cervical cancer Jiangsu Hengrui Pharmaceuticals announced that its SHR-A2102 ADC has been granted Breakthrough Therapy Designation […]
Weekly Digest – April 2026 Weekly Digest – April 2026 23 April 2026: Mabwell initiates phase 3 clinical study of its Nectin-4 targeting ADC 9MW2821 for the treatment of TNBC Mabwell announced the initiation of a Phase 3 clinical trial […]
Weekly Digest – April 2026 Weekly Digest – April 2026 23 April 2026: Servier completes the acquisition of Day One Biopharmaceuticals Servier has completed the acquisition of Day One Biopharmaceuticals in a deal valued at approximately $2.5 billion, strengthening its […]
Weekly Digest – April 2026 Weekly Digest – April 2026 10 April 2026: Disitamab Vedotin approved in china as first line therapy for HER2 expressing urothelial carcinoma RemeGen has received approval in China for disitamab vedotin (RC48, Aidixi) in combination […]
Weekly Digest – April 2026 Weekly Digest – April 2026 13 April 2026: Ifinatamab Deruxtecan receives U.S. Priority Review for previously treated extensive-stage SCLC progressing after platinum-based chemotherapy Daiichi Sankyo and Merck have received U.S. FDA acceptance and Priority Review […]
Weekly Digest – April 2026 Weekly Digest – April 2026 14 April 2026: GlycoNex receives PMDA approval in Japan to initiate first-in-human phase 1 trial of GNX1021 in gastrointestinal cancers GlycoNex, Inc. has received approval from Japan’s Pharmaceuticals and Medical […]
Weekly Digest – April 2026 Weekly Digest – April 2026 15 April 2026: CSPC Pharmaceutical Group Limited obtains NMPA clinical trial approval for TF-targeted ADC SYS6051 in China CSPC Pharmaceutical Group Limited has received clinical trial approval in China for […]
